Events Archives - Page 74 of 128

1 minute read

Ensysce CEO Dr. Lynn Kirkpatrick To Present Featured Case Study Of MPAR Overdose Protection Platform Accelerated Development, April 19 2023, At 11:30am ET As A Featured Speaker

April 19, 9:27 AM

~ Global QUOTIENT LIFE SCIENCES Webinar Today, April 19, 2023 at 11:30am ET ~ SAN DIEGO, CA / ACCESSWIRE / April 19, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC),

ENSC

3 minute read

Vincerx Pharma Presents Preclinical Data On VIP924, A First-in-Class Antibody-Drug Conjugate, At The 2023 American Association For Cancer Research Annual Meeting

By Happy Mohamed

April 19, 9:23 AM

Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today presented a poster of VIP924

VINC

2 minute read

Actinium Highlights First-In-Class HER3 Targeted Radiotherapy Data Demonstrating Potent Anti-Cancer Activity Of In Ovarian And Colorectal Cancer Models At The AACR Annual Meeting

By Happy Mohamed

April 19, 8:46 AM

- Highly significant (p<0.0001) reduction in tumor volume in ovarian cancer model when using HER3-ARC conjugated to either Actinium-225 or Lutetium-177 compared to bevacizumab (Avastin) - HER3 is

ATNM

3 minute read

Biomea Fusion To Present Late Breaking Data From Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 In Patients With Type 2 Diabetes, At The ADA 83rd Scientific Sessions 2023 In June

By Happy Mohamed

April 19, 8:35 AM

New clinical data from COVALENT-111 will be featured during the Late-Breaking Poster Presentations at the Scientific Sessions Biomea to hold an investor and KOL event during the Scientific Sessions REDWOOD CITY,

BMEA

3 minute read

ORIC Pharmaceuticals Presents Preclinical Data On Two Programs At The 2023 American Association For Cancer Research Annual Meeting

By Happy Mohamed

April 18, 4:27 PM

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented two preclinical poster presentations at the 2023

ORIC

2 minute read

Sensei Biotherapeutics Presents New Preclinical Data On SNS-103 Targeting ENTPDase1 (CD39) At The American Association For Cancer Research Annual Meeting 2023

By Happy Mohamed

April 18, 4:16 PM

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today presented new preclinical data on its SNS-103

SNSE

5 minute read

Sonnet BioTherapeutics Announces Updated Clinical Data For SON-1010 At The 2023 American Association For Cancer Research Annual Meeting

By Happy Mohamed

April 18, 4:10 PM

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the safety of SON-1010

SONN

2 minute read

MiNK Therapeutics Announces Clinical Data Of Allogeneic iNKT Cells In Solid Tumor Cancers At The AACR Annual Meeting

By Happy Mohamed

April 18, 1:38 PM

Allogeneic iNKTs, agenT-797, administered alone or in combination with anti-PD-1 therapy, shows activity in patients with refractory solid tumor cancers. In a patient with metastatic gastric cancer who had no response

INKT

4 minute read

Harpoon Therapeutics Presents Preclinical Results For Novel T Cell Engagers HPN217 And HPN328 At AACR 2023

By Happy Mohamed

April 18, 1:37 PM

Preclinical results for HPN328 suggest potential for long-term anti-tumor immunity and durable responses in patients, as well as utility of combining anti-PD-L1 antibodies to enhance anti-tumor

HARP

3 minute read

Moleculin Announces Presentation Of Pharmacokinetics And Tissue-Organ Distribution Data Demonstrating High Antitumor Activity Of Annamycin In Preclinical Cancer Models

By Happy Mohamed

April 18, 1:36 PM

Sponsored research data presented in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023 Annamycin demonstrated increased penetration and accumulation in the liver, which

MBRX